Abstract:<p>A goal of the WHO strategy on the elimination of hepatitis as a public threat is a 65% reduction in the attributable mortality. Deaths related to hepatitis B and C infections are mostly due to decompensated cirrhosis and hepatocellular carcinoma (HCC) but accurately measuring mortality is challenging as death certificates often do not capture the underlying disease. The aim of this collaborative study between European Centre for Disease Prevention and Control (ECDC) and the European Association for the Study of the Liver (EASL) was to assess a WHO‐developed protocol to support countries in implementing studies to collect data on the fraction of cirrhosis and hepatocellular carcinoma attributable to hepatitis B and C. Three sentinel sites (in Bulgaria, Norway and Portugal) collected data for patients first admitted or seen in their centres during 2016. Patients with cirrhosis or HCC were identified through patient files or healthcare databases using ICD‐10 codes. The proportion of patients with cirrhosis and HCC who tested positive for HBV and HCV were calculated to estimate the aetiological fractions. After the pilot study was completed, each site was asked about the feasibility and acceptability of the protocol. A total of 1249 patients presenting with cirrhosis and/or HCC were evaluated across the three sites. The prevalence of HBV and HCV among cases of cirrhosis showed that in Norway and Portugal, HCV was responsible for about one quarter of the cases, whereas in Bulgaria, HBV was more common. HCV was responsible for more than one‐third of HCC cases in Norway and Portugal, while in Bulgaria HBV was more frequent as HCC underlying cause. Results obtained during the pilot study were comparable to published estimates obtained through statistical modelling or meta‐analyses. Several challenges were reported from the sites involved in the pilot including the considerable time needed for reviewing the hospital records and extracting the patient's data.The pilot demonstrated the feasibility of collecting data on the prevalence of HBV and HCV infection among patients with cirrhosis and HCC in sentinel sites. This method can be used to estimate mortality attributable to HBV and HCV for elimination monitoring. Where easily implementable, sentinel studies are the best way to empower countries, get up‐to date data, and closely monitor the changes in the attributable fraction at a country level.</p>

Prevalence of chronic hepatitis C infection in the general population: results from a national survey, Estonia, July to December 2022

Prevalence of chronic hepatitis C infection in the general population: results from a national survey, Romania, 2020 to 2023

Successful hepatitis B and C screening in the health check-up in the German primary care setting

Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study.

Hepatitis C prevalence in Denmark in 2016-An updated estimate using multiple national registers

Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets

Hepatitis C virus infection in Eastern Europe

Hepatitis C community prevalence is over-estimated: a prospective, birth cohort study

[Seroepidemiological Investigation of Hepatitis C Virus in Zhejiang Province: a Hospital-Based Study].

Prevalence of HCV infection in Europe in the DAA era: Review

Hepatitis E virus infection in different groups of Estonian patients and people who inject drugs

Up-to-date Epidemiology of Chronic Hepatitis C Virus Infection among Bulgarian Patients: a Single Centre Experience

Hepatitis C in Poland in 2019

Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019

Hepatitis C in the Russian Federation: challenges and future directions

Determination of hepatitis C virus viremia and genotype distribution in Turkish citizens and immigrants from 2018 to 2022

Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C

Seroprevalence of Hepatitis C Virus and Factors Associated with It in Armenia, 2021

Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general population

Five-year experience of express testing of the population of the Samara Region for hepatitis C and B virus infection using a mobile laboratory

Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review